Sodium Hyaluronate Eye Drops Instructions
Release time:
2020-07-07
Approval Date: May 21, 2007
Revision Date: December 21, 2010
Peak
Sodium Hyaluronate Eye Drops Instructions
[Drug Name]
General Name: Sodium Hyaluronate Eye Drops
English Name: Sodium Hyaluronate Hyaluronate Eye Drops
Chinese Pinyin: Bolisuanna Diyanye
[Ingredients]
The main ingredient of this product is sodium hyaluronate.
Chemical Name:(1 → 4)-O-β-D-Glucuronic Acid-(1 → 3)-2-Acetylamino -2-Deoxy-β-D-Glucose
Molecular Formula:(C14H20NNaO11)n
[Character] This product is a colorless and clear slightly viscous liquid.
[Indications]
is used for keratoconjunctival epithelial injury caused by internal diseases such as Sjogren's syndrome (Sjogren,s syndrome), Sjogren's syndrome (Stevens-Johnson syndrome), dry eye (dry eye) and various external diseases (such as surgery, drug-induced, trauma, wearing contact lenses, etc.). It is especially suitable for patients with Sjogren's syndrome and Sjogren's syndrome requiring long-term medication.
[Specification] 5ml:5mg(0.1%)
[Usage and Dosage]
Eye drops, usually 1 drop at a time, 5-6 times a day, can be appropriately increased or decreased according to symptoms. Generally, 0.1% of the preparation is used, and 0.3% of the preparation is used in cases where the effect is not good.
[Adverse Reactions]
(1) Sometimes corneal disorders such as itching, irritation, congestion, and diffuse superficial keratitis may occur. If the above symptoms occur, the medication should be stopped immediately.
(2) Allergy: Occasional blepharitis, blepharitis and other allergic symptoms, such as allergy, should immediately stop medication.
[Taboo] is not clear.
[Precautions]
This product is only used for eye drops. Be careful not to contact the mouth of the eye drop bottle with the eye when dropping the eye. Please close the bottle cap tightly after use. After opening, do not use the soft contact lens without removing it.
[Use in pregnant and lactating women] is not clear.
Pediatric use is not clear.
[Geriatric use] is not clear.
Drug interaction is not clear.
Overdose is unknown.
[Pharmacology and Toxicology]
Sodium hyaluronate is a natural polymer compound, which is an important component of tissue matrix. It has good viscoelasticity and has a protective effect on cornea. Combined with fibronectin, it promotes the connection and extension of corneal epithelial cells and accelerates corneal wound healing. In addition, sodium hyaluronate molecules have strong hydrophilic ability and lubrication, which can stabilize the tear film, prevent keratoconjunctival dryness and reduce the friction of eye tissue, and relieve the discomfort symptoms of dry eye.
[Pharmacokinetics]
After 14C-labeled 0.1 sodium hyaluronate eye drops are instilled in rabbits, strong radioactivity can be detected in conjunctiva, external eye muscle and sclera within 0.5h, with the strongest radioactivity in conjunctiva, weak radioactivity can be detected in cornea, retina and choroid, while no radioactivity can be detected in aqueous humor, iris, ciliary body, crystal and vitreous. The radioactivity of the conjunctiva dropped below the threshold after 24h. Healthy people were given 0.1 sodium hyaluronate eye drops on the first day of monocular eyes, and were changed to 0.5 sodium hyaluronate eye drops on the second day, 1 drop once, 5 times a day, and continued to use sodium hyaluronate eye drops on the third to ninth days, 13 times a day, for 7 consecutive days. The concentration of sodium hyaluronate in serum was determined at the beginning of the drop, on the third day, the ninth day and the tenth day, and all of them were below the detection limit (10?g/ml), which was the same as that of the drop.
[Storage] Shade and place in a cool place (not more than 20 ℃).
[packaging] plastic bottles, 5ml per bottle.
[Validity Period] 24 Months
[Implementation Standard] YBH04002006
[Approval Document Number] National Medicine Standard H20063950
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: 368 Jinqu Road, Jinhua Industrial Park, Zhejiang Province Zip Code: 321016
Tel: 0579-82273183
Fax: 0579-82272272
Website:
www.zjjy.com.cn
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page